Brokerages Set Envista Holdings Corporation (NYSE:NVST) Target Price at $20.23

Shares of Envista Holdings Corporation (NYSE:NVST - Get Free Report) have been given an average recommendation of "Hold" by the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $20.23.

A number of equities analysts have issued reports on the company. Piper Sandler cut their target price on Envista from $18.00 to $17.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. Bank of America cut their target price on Envista from $26.00 to $23.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Baird R W raised Envista from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 27th. Morgan Stanley set a $16.00 target price on Envista in a research report on Tuesday, April 15th. Finally, Evercore ISI upped their target price on Envista from $19.00 to $23.00 and gave the company an "outperform" rating in a research report on Wednesday, July 9th.

Hedge Funds Weigh In On Envista

Several institutional investors have recently bought and sold shares of NVST. UMB Bank n.a. lifted its holdings in shares of Envista by 214.4% in the first quarter. UMB Bank n.a. now owns 2,094 shares of the company's stock valued at $36,000 after purchasing an additional 1,428 shares in the last quarter. Parallel Advisors LLC grew its position in Envista by 100.1% during the second quarter. Parallel Advisors LLC now owns 2,792 shares of the company's stock worth $55,000 after buying an additional 1,397 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp acquired a new stake in Envista during the fourth quarter worth approximately $86,000. Palouse Capital Management Inc. lifted its stake in Envista by 14.4% during the first quarter. Palouse Capital Management Inc. now owns 9,444 shares of the company's stock worth $163,000 after purchasing an additional 1,186 shares during the last quarter. Finally, FourThought Financial Partners LLC bought a new stake in Envista during the first quarter worth $180,000.

Envista Price Performance

Envista stock traded down $0.04 during midday trading on Friday, reaching $19.47. 1,551,441 shares of the company were exchanged, compared to its average volume of 2,461,387. The company has a market capitalization of $3.30 billion, a price-to-earnings ratio of -2.98, a P/E/G ratio of 1.23 and a beta of 1.00. The firm's 50-day simple moving average is $18.91 and its 200-day simple moving average is $18.53. Envista has a 1 year low of $14.22 and a 1 year high of $23.00. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.82 and a current ratio of 2.12.

Envista (NYSE:NVST - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.20 by $0.04. The company had revenue of $616.90 million during the quarter, compared to analysts' expectations of $608.17 million. Envista had a positive return on equity of 4.07% and a negative net margin of 44.90%. The firm's revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.26 EPS. On average, analysts anticipate that Envista will post 1 EPS for the current year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.